000292299 001__ 292299
000292299 005__ 20250321101759.0
000292299 0247_ $$2doi$$a10.1038/s41541-024-00941-w
000292299 0247_ $$2pmid$$apmid:39138224
000292299 0247_ $$2altmetric$$aaltmetric:166277236
000292299 037__ $$aDKFZ-2024-01659
000292299 041__ $$aEnglish
000292299 082__ $$a610
000292299 1001_ $$00000-0001-9065-4734$$aGray, Penelope$$b0
000292299 245__ $$aLack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study.
000292299 260__ $$a[London]$$bNature Publishing Group$$c2024
000292299 3367_ $$2DRIVER$$aarticle
000292299 3367_ $$2DataCite$$aOutput Types/Journal article
000292299 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1723639538_8152
000292299 3367_ $$2BibTeX$$aARTICLE
000292299 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000292299 3367_ $$00$$2EndNote$$aJournal Article
000292299 500__ $$a#EA:D335#
000292299 520__ $$aAlthough HPV vaccines are highly efficacious, a notable proportion of quadrivalent vaccinees are HPV18 seronegative post-vaccination. We have investigated this findings' validity by comparing vaccine-induced antibody responses using two different immunoassays. 6558 16-17-year-old females participated in the FUTURE II (NCT00092534) and PATRICIA (NCT00122681) trials in 2002-2004. Both the quadrivalent and bivalent vaccine recipients (QVR and BVR) received three doses. Twelve-year follow-up for 648 vaccinees was conducted by the Finnish Maternity Cohort. The presence of neutralising and binding HPV antibodies was analysed via HPV pseudovirion-based neutralisation and pseudovirion-binding assays. Four percent and 14.3% of the QVRs were seronegative for neutralising and binding antibodies to HPV16 and HPV18, respectively. No BVRs were HPV16/18 seronegative post-vaccination. The antibody titres were strongly correlated between the assays, Pearson's correlation coefficient, r[HPV16] = 0.92 and 0.85, and r[HPV18] = 0.91 and 0.86 among the QVRs and BVRs respectively. Fourteen percent of QVRs lacked detectable HPV18 antibodies in long-term follow-up.
000292299 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000292299 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000292299 7001_ $$00000-0001-6624-4524$$aMariz, Filipe Colaço$$b1$$eFirst author
000292299 7001_ $$aEklund, Carina$$b2
000292299 7001_ $$aEriksson, Tiina$$b3
000292299 7001_ $$aFaust, Helena$$b4
000292299 7001_ $$aKann, Hanna$$b5
000292299 7001_ $$0P:(DE-He78)4cbf38280ce272e37f96081b070dd46a$$aMüller, Martin$$b6$$udkfz
000292299 7001_ $$aPaavonen, Jorma$$b7
000292299 7001_ $$00000-0002-0813-7031$$aPimenoff, Ville N$$b8
000292299 7001_ $$aSehr, Peter$$b9
000292299 7001_ $$aSurcel, Heljä-Marja$$b10
000292299 7001_ $$aDillner, Joakim$$b11
000292299 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b12$$udkfz
000292299 7001_ $$aLehtinen, Matti$$b13
000292299 773__ $$0PERI:(DE-600)2882262-6$$a10.1038/s41541-024-00941-w$$gVol. 9, no. 1, p. 146$$n1$$p146$$tnpj vaccines$$v9$$x2059-0105$$y2024
000292299 8564_ $$uhttps://inrepo02.dkfz.de/record/292299/files/s41541-024-00941-w.pdf
000292299 8564_ $$uhttps://inrepo02.dkfz.de/record/292299/files/s41541-024-00941-w.pdf?subformat=pdfa$$xpdfa
000292299 909CO $$ooai:inrepo02.dkfz.de:292299$$pVDB
000292299 9101_ $$0I:(DE-588b)2036810-0$$60000-0001-6624-4524$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000292299 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4cbf38280ce272e37f96081b070dd46a$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000292299 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000292299 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000292299 9141_ $$y2024
000292299 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNPJ VACCINES : 2022$$d2023-08-24
000292299 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000292299 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000292299 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-24
000292299 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:11:19Z
000292299 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:11:19Z
000292299 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:11:19Z
000292299 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-04-12T15:11:19Z
000292299 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000292299 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-24
000292299 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-24
000292299 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000292299 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-24
000292299 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-24
000292299 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNPJ VACCINES : 2022$$d2023-08-24
000292299 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-24
000292299 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-24
000292299 9200_ $$0I:(DE-He78)D335-20160331$$kD335$$lTumorvirus-spez. Vakzinierungsstrategie$$x0
000292299 9201_ $$0I:(DE-He78)D335-20160331$$kD335$$lTumorvirus-spez. Vakzinierungsstrategie$$x0
000292299 9201_ $$0I:(DE-He78)D320-20160331$$kD320$$lInfektionen und Krebs-Epidemiologie$$x1
000292299 980__ $$ajournal
000292299 980__ $$aVDB
000292299 980__ $$aI:(DE-He78)D335-20160331
000292299 980__ $$aI:(DE-He78)D320-20160331
000292299 980__ $$aUNRESTRICTED